1. Home
  2. ABCL vs MESO Comparison

ABCL vs MESO Comparison

Compare ABCL & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • MESO
  • Stock Information
  • Founded
  • ABCL 2012
  • MESO 2004
  • Country
  • ABCL Canada
  • MESO Australia
  • Employees
  • ABCL N/A
  • MESO N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ABCL Health Care
  • MESO Health Care
  • Exchange
  • ABCL Nasdaq
  • MESO Nasdaq
  • Market Cap
  • ABCL 1.1B
  • MESO 1.3B
  • IPO Year
  • ABCL 2020
  • MESO N/A
  • Fundamental
  • Price
  • ABCL $4.39
  • MESO $15.81
  • Analyst Decision
  • ABCL Strong Buy
  • MESO Buy
  • Analyst Count
  • ABCL 5
  • MESO 4
  • Target Price
  • ABCL $8.00
  • MESO $18.00
  • AVG Volume (30 Days)
  • ABCL 5.5M
  • MESO 148.6K
  • Earning Date
  • ABCL 08-07-2025
  • MESO 09-02-2025
  • Dividend Yield
  • ABCL N/A
  • MESO N/A
  • EPS Growth
  • ABCL N/A
  • MESO N/A
  • EPS
  • ABCL N/A
  • MESO N/A
  • Revenue
  • ABCL $32,875,999.00
  • MESO $5,670,000.00
  • Revenue This Year
  • ABCL N/A
  • MESO $177.23
  • Revenue Next Year
  • ABCL $71.11
  • MESO $314.04
  • P/E Ratio
  • ABCL N/A
  • MESO N/A
  • Revenue Growth
  • ABCL N/A
  • MESO N/A
  • 52 Week Low
  • ABCL $1.89
  • MESO $6.00
  • 52 Week High
  • ABCL $5.82
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 51.44
  • MESO 58.97
  • Support Level
  • ABCL $4.01
  • MESO $14.68
  • Resistance Level
  • ABCL $4.81
  • MESO $16.38
  • Average True Range (ATR)
  • ABCL 0.36
  • MESO 0.44
  • MACD
  • ABCL -0.05
  • MESO -0.14
  • Stochastic Oscillator
  • ABCL 42.59
  • MESO 67.05

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: